Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Enloe Medical Center — Chico, California
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- UC San Diego Moores Cancer Center — La Jolla, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in California: - Providence - Saint Joseph Home Health - Anaheim — Anaheim, California
- The Oncology Institute of Hope and Innovation - Corporate Office — Cerritos, California
- Local Institution - 007-777 — Fountain Valley, California
- Local Institution - 007-778 — Laguna Hills, California
- Local Institution - 007-898-B — Long Beach, California
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in California: - Alta Bates Summit Medical Center Comprehensive Cancer Center — Berkeley, California
- UC San Diego Medical Center - Encinitas — Encinitas, California
- Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center — Fullerton, California
- UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Pavilion — La Jolla, California
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in California: - Clinical Study Site — Alameda, California
- Clinical Study Site — Anaheim, California
- Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Cerritos, California
- Clinical Study Site — Los Angeles, California
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in California: - UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
- Profound Research LLC — Oceanside, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- Stanford Cancer Center — Palo Alto, California
- Kaiser Permanente San Diego Mission Road — San Diego, California
Phase 3 Recruiting Industry
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…
Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in California: - Clinical Research Advisors, LLC — Beverly Hills, California
- Clinical Research Advisors - Encino — Encino, California
- Clinical Research Advisors - West Hollywood — Los Angeles, California
- Clinical Research Advisors - Korea Town — Los Angeles, California
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in California: - Local Institution - 0581 — Fullerton, California
- Local Institution - 0682 — Loma Linda, California
- Helios Clinical Research — Long Beach, California
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in California: - The Oncology Institute (TOI) Clinical Research - 1109 — Cerritos, California
- Emad Ibrahim MD Inc. - 1147 — Redlands, California
- UC Davis Comprehensive Cancer Center - 1103 — Sacramento, California
- Bass Medical Group - 1155 — Walnut Creek, California
Phase 3 Recruiting Industry
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…
Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in California: - Research Site — Fountain Valley, California
- Research Site — Santa Rosa, California
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in California: - UCSD — La Jolla, California
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in California: - John Muir Clinical Research Center — Concord, California
- University Of California - San Diego Moores Cancer Center — La Jolla, California
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in California: - St. Jude Herritage Medical Group — Fullerton, California
- Hoag Family Cancer Institute - Hoag Memorial Hospital — Newport Beach, California
- Sutter Institute for Medical Research — Sacramento, California
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building — Irvine, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in California: - ClinRé 001-022 (Premier Cancer Care and Infusion Center) — Fresno, California
- OPN Healthcare, Inc. — Glendale, California
- University of California Irvine — Irvine, California
- Sutter Health — Roseville, California
- University of California San Francisco — San Francisco, California
Phase 3 Recruiting Industry
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…
Sponsor: Amgen
NCT ID: NCT05920356
Sites in California: - Sansum Clinic — Santa Barbara, California
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in California: - Chan Soon-Shiong Institute for Medicine — El Segundo, California
- MemorialCare - Orange Coast Medical Center — Fountain Valley, California
- OPN Healthcare INC — Glendale, California
- OPN Healthcare INC/ Cancer and Blood Specialty Clinic — Los Alamitos, California
Phase 2, Phase 3 Recruiting Industry
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…
Sponsor: AbbVie
NCT ID: NCT06236438
Sites in California: - Moores Cancer Center /ID# 267782 — La Jolla, California
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in California: - CBCC Global Research, Inc. ( Site 0123) — Bakersfield, California
- Beverly Hills Cancer Center ( Site 0116) — Beverly Hills, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in California: - Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 3 Recruiting Industry
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses o…
Sponsor: Takeda
NCT ID: NCT07217301
Sites in California: - Memorial Care — Fountain Valley, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Translation Research in Oncology- US, INC (TRIO-US) — Torrance, California
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Sites in California: - Ventura Clinical Trials — Ventura, California
Phase 3 Recruiting Academic/Other
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Sponsor: Maximilian Diehn
NCT ID: NCT04585490
Sites in California: - Stanford University — Stanford, California